technetium tc 99m sulesomab
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Jun 14, 2017 (NCT03112356)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Unspecified targetBINDING AGENT
binding agent
- Unspecified targetOTHER
Diagnostic agent
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Imaging
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109524 ↗
- ChEMBLCHEMBL2108809 ↗
Also known as
- 99mtc-leukoscan
- 99mtc-sulesomab
- immu-mn3
- immu-mn3
- immu-mn-3
- leukoscan
- leukoscan
- monoclonal antibody immu-mn3
- sulesomab
- sulesomab
- sulesomab
- sulesomab tc
- technetium (99mtc) sulesomab
- technetium tc 99m sulesomab
- technetium tc 99m sulesomab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03112356 | Phase 4 | Jun 14, 2017 | University of Lyon |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Lyon | Academic/Hospital | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1